Guarding the frontiers: The biology of type III interferons

Nature Immunology

Volumn 16, Issue 8, 2015, Pages 802-809

  Wack, Andreas ^a   Terczyńska Dyla, Ewa ^b   Hartmann, Rune ^b  

^a THE FRANCIS CRICK INSTITUTE   (United Kingdom)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON; INTERFERON TYPE III; PEGINTERFERON; UNCLASSIFIED DRUG; IFNL4 PROTEIN, HUMAN; IL28A PROTEIN, HUMAN; IL28B PROTEIN, HUMAN; IL29 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE;

BIOLOGY; EPITHELIUM CELL; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; LIVER; LIVER CELL; MIXED INFECTION; MUCOSAL IMMUNITY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE REACTION; VIRAL CLEARANCE; BIOLOGICAL MODEL; CHROMOSOME 19; GENETICS; HEPACIVIRUS; HEPATITIS C; IMMUNOLOGY; VIROLOGY;

CHROMOSOMES, HUMAN, PAIR 19; HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HUMANS; INTERLEUKINS; MODELS, IMMUNOLOGICAL;

EID: 84937779845     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni.3212     Document Type: Review

References (110)

1. Kotenko, S.V. et al. IFN-λ s mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77 (2003).
2. Sheppard, P. et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68 (2003).
3. Fox, B.A., Sheppard, P.O. & O'Hara, P.J. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-λ family. PLoS ONE 4, e4933 (2009).
4. Prokunina-Olsson, L. et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 45, 164-171 (2013).
5. Dumoutier, L. et al. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-λ 1: similarities with type I interferon signaling. J. Biol. Chem. 279, 32269-32274 (2004).
6. Zhou, Z. et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J. Virol. 81, 7749-7758 (2007).
7. Doyle, S.E. et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44, 896-906 (2006).
8. Marcello, T. et al. Interferons α and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887-1898 (2006).
9. Crotta, S. et al. Type I and type III interferons drive redundant amplification loops to induce a transcriptional signature in influenza-infected airway epithelia. PLoS Pathog. 9, e1003773 (2013).
10. Malakhova, O.A. et al. UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity. EMBO J. 25, 2358-2367 (2006).
11. François-Newton, V. et al. USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon α response. PLoS ONE 6, e22200 (2011).
12. Makowska, Z., Duong, F.H., Trincucci, G., Tough, D.F. & Heim, M.H. Interferon-βand interferon-λ signaling is not affected by interferon-induced refractoriness to interferon-α in vivo. Hepatology 53, 1154-1163 (2011).
13. Bolen, C.R., Ding, S., Robek, M.D. & Kleinstein, S.H. Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression. Hepatology 59, 1262-1272 (2014).
14. Jilg, N. et al. Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus. Hepatology 59, 1250-1261 (2014).
15. Burkart, C. et al. Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10. EMBO Mol. Med. 5, 967-982 (2013).
16. Gad, H.H. et al. Interferon-λ is functionally an interferon but structurally related to the IL-10 family. J. Biol. Chem. 284, 20869-20875 (2009).
17. Miknis, Z.J. et al. Crystal structure of human interferon-λ1 in complex with its high-affinity receptor interferon-λR1. J. Mol. Biol. 404, 650-664 (2010).
18. Mordstein, M. et al. λ interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J. Virol. 84, 5670-5677 (2010).
19. Sommereyns, C., Paul, S., Staeheli, P. & Michiels, T. IFN-λ (IFN-λ) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog. 4, e1000017 (2008).
20. Pulverer, J.E. et al. Temporal and spatial resolution of type I and III interferon responses in vivo. J. Virol. 84, 8626-8638 (2010).
21. Pott, J. et al. IFN-λ determines the intestinal epithelial antiviral host defense. Proc. Natl. Acad. Sci. USA 108, 7944-7949 (2011).
22. Hermant, P. et al. Human but not mouse hepatocytes respond to interferon-λin vivo. PLoS ONE 9, e87906 (2014).
23. Hermant, P. & Michiels, T. Interferon-λ in the context of viral infections: production, response and therapeutic implications. J. Innate Immun. 6, 563-574 (2014).
24. Anggakusuma et al. Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons. J. Virol. 89, 3833-3845 (2015).
25. Meager, A., Visvalingam, K., Dilger, P., Bryan, D. & Wadhwa, M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 31, 109-118 (2005).
26. Muir, A.J. et al. Phase 1b study of PEGylated interferon-λ1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 52, 822-832 (2010).
27. Lauber, C. et al. Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells. Genes Immun. doi:10.1038/ gene.2015.23 (11 June 2015).
28. Witte, K. et al. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 10, 702-714 (2009).
29. Ding, S., Khoury-Hanold, W., Iwasaki, A. & Robek, M.D. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol. 12, e1001758 (2014).
30. Durbin, R.K., Kotenko, S.V. & Durbin, J.E. Interferon induction and function at the mucosal surface. Immunol. Rev. 255, 25-39 (2013).
31. Ank, N. et al. λ interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 80, 4501-4509 (2006).
32. Donnelly, R.P. & Kotenko, S.V. Interferon-λ : a new addition to an old family. J. Interferon Cytokine Res. 30, 555-564 (2010).
33. Coccia, E.M. et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796-805 (2004).
34. Osterlund, P. et al. Gene expression and antiviral activity of α/β interferons and interleukin-29 in virus-infected human myeloid dendritic cells. J. Virol. 79, 9608-9617 (2005).
35. + DCs are major producers of IFN-λ in response to poly IC. J. Exp. Med. 207, 2703-2717 (2010).
36. Hillyer, P. et al. Expression profiles of human interferon-α and interferon-λ subtypes are ligand- and cell-dependent. Immunol. Cell Biol. 90, 774-783 (2012).
37. Melchjorsen, J., Siren, J., Julkunen, I., Paludan, S.R. & Matikainen, S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. J. Gen. Virol. 87, 1099-1108 (2006).
38. Khaitov, M.R. et al. Respiratory virus induction of α-, β- and λ-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 64, 375-386 (2009).
39. Wang, J. et al. Differentiated human alveolar type II cells secrete antiviral il-29 (IFN-1) in response to influenza A infection. J. Immunol. 182, 1296-1304 (2009).
40. Ioannidis, I., Ye, F., McNally, B., Willette, M. & Flano, E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. J. Virol. 87, 3261-3270 (2013).
41. Jewell, N.A. et al. λ interferon is the predominant interferon induced by influenza A virus infection in vivo. J. Virol. 84, 11515-11522 (2010).
42. Osterlund, P.I., Pietila, T.E., Veckman, V., Kotenko, S.V. & Julkunen, I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-λ) genes. J. Immunol. 179, 3434-3442 (2007).
43. Onoguchi, K. et al. Viral infections activate types I and III interferon genes through a common mechanism. J. Biol. Chem. 282, 7576-7581 (2007).
44. Kotenko, S.V. IFN-λs. Curr. Opin. Immunol. 23, 583-590 (2011).
45. Thomson, S.J. et al. The role of transposable elements in the regulation of IFN-λ1 gene expression. Proc. Natl. Acad. Sci. USA 106, 11564-11569 (2009).
46. Siegel, R., Eskdale, J. & Gallagher, G. Regulation of IFN-λ1 promoter activity (IFN-λ1/IL-29) in human airway epithelial cells. J. Immunol. 187, 5636-5644 (2011).
47. Swider, A., Siegel, R., Eskdale, J. & Gallagher, G. Regulation of interferon λ-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells. Cytokine 65, 17-23 (2014).
48. Odendall, C. et al. Diverse intracellular pathogens activate type III interferon expression from peroxisomes. Nat. Immunol. 15, 717-726 (2014).
49. Dixit, E. et al. Peroxisomes are signaling platforms for antiviral innate immunity. Cell 141, 668-681 (2010).
50. Lee, H.C., Narayanan, S., Park, S.J., Seong, S.Y. & Hahn, Y.S. Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3. IRF-7.NF-κB complex. J. Biol. Chem. 289, 5310-5319 (2014).
51. Poss, Z.C., Ebmeier, C.C. & Taatjes, D.J. The Mediator complex and transcription regulation. Crit. Rev. Biochem. Mol. Biol. 48, 575-608 (2013).
52. Griffiths, S.J. et al. A systematic analysis of host factors reveals a Med23- interferon-λ regulatory axis against herpes simplex virus type 1 replication. PLoS Pathog. 9, e1003514 (2013).
53. Mahlakõiv, T., Hernandez, P., Gronke, K., Diefenbach, A. & Staeheli, P. Leukocyte-derived IFN-α/β and epithelial IFN-λ constitute a compartmentalized mucosal defense system that restricts enteric virus infections. PLoS Pathog. 11, e1004782 (2015).
54. Nice, T.J. et al. Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity. Science 347, 269-273 (2015).
55. Baldridge, M.T. et al. Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection. Science 347, 266-269 (2015).
56. Ank, N. et al. An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity. J. Immunol. 180, 2474-2485 (2008).
57. Lazear, H.M. et al. Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier. Sci. Transl. Med. 7, 284ra259 (2015).
58. Mordstein, M. et al. Interferon-λ contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog. 4, e1000151 (2008).
59. Muir, A.J. et al. A randomized phase 2b study of peginterferon λ-1a for the treatment of chronic hcv infection. J. Hepatol. 61, 1238-1246 (2014).
60. Yin, Z. et al. Type III IFNs are produced by and stimulate human plasmacytoid dendritic cells. J. Immunol. 189, 2735-2745 (2012).
61. Liu, B.S., Janssen, H.L. & Boonstra, A. IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression. Blood 117, 2385-2395 (2011).
62. Megjugorac, N.J., Gallagher, G.E. & Gallagher, G. Modulation of human plasmacytoid DC function by IFN-λ 1 (IL-29). J. Leukoc. Biol. 86, 1359-1363 (2009).
63. Koltsida, O. et al. IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol. Med. 3, 348-361 (2011).
64. Dring, M.M. et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc. Natl. Acad. Sci. USA 108, 5736-5741 (2011).
65. Krämer, B. et al. Do λ-IFNs IL28A and IL28B act on human natural killer cells? Proc. Natl. Acad. Sci. USA 108, E519-E520 (2011).
66. de Groen, R.A. et al. IFN-λ-mediated IL-12 production in macrophages induces IFN-γ production in human NK cells. Eur. J. Immunol. 45, 250-259 (2015).
67. Souza-Fonseca-Guimaraes, F. et al. NK cells require IL-28R for optimal in vivo activity. Proc. Natl. Acad. Sci. USA 112, E2376-E2384 (2015).
68. Blazek, K. et al. IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production. J. Exp. Med. 212, 845-853 (2015).
69. McNab, F., Mayer-Barber, K., Sher, A., Wack, A. & O'Garra, A. Type I interferons in infectious disease. Nat. Rev. Immunol. 15, 87-103 (2015).
70. Dai, J., Megjugorac, N.J., Gallagher, G.E., Yu, R.Y. & Gallagher, G. IFN-λ1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood 113, 5829-5838 (2009).
71. Egli, A. et al. IL-28B is a key regulator of B- and T-cell vaccine responses against influenza. PLoS Pathog. 10, e1004556 (2014).
72. Edwards, M.R. & Johnston, S.L. Interferon-λ as a new approach for treatment of allergic asthma? EMBO Mol. Med. 3, 306-308 (2011).
73. Davidson, S., Maini, M.K. & Wack, A. Disease-promoting effects of type I interferons in viral, bacterial, and coinfections. J. Interferon Cytokine Res. 35, 252-264 (2015).
74. Davidson, S., Crotta, S., McCabe, T.M. & Wack, A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat. Commun. 5, 3864 (2014).
75. Bosinger, S.E. et al. Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J. Clin. Invest. 119, 3556-3572 (2009).
76. Jacquelin, B. et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119, 3544-3555 (2009).
77. Mandl, J.N. et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat. Med. 14, 1077-1087 (2008).
78. Micco, L. et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-α therapy of chronic hepatitis B. J. Hepatol. 58, 225-233 (2013).
79. Penna, A. et al. Peginterferon-α does not improve early peripheral blood HBVspecific T-cell responses in HBeAg-negative chronic hepatitis. J. Hepatol. 56, 1239-1246 (2012).
80. Teijaro, J.R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207-211 (2013).
81. Wilson, E.B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202-207 (2013).
82. Rayamajhi, M., Humann, J., Penheiter, K., Andreasen, K. & Lenz, L.L. Induction of IFN-αβ enables Listeria monocytogenes to suppress macrophage activation by IFN-γ. J. Exp. Med. 207, 327-337 (2010).
83. Teles, R.M. et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339, 1448-1453 (2013).
84. Antonelli, L.R. et al. Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120, 1674-1682 (2010).
85. Redford, P.S. et al. Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type I interferon receptor-dependent pathway. J. Infect. Dis. 209, 270-274 (2014).
86. Shepard, C.W., Finelli, L. & Alter, M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
87. Ge, D. et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
88. Suppiah, V. et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
89. Tanaka, Y. et al. Genome-wide association of IL28B with response to PEGylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
90. Rauch, A. et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138, 1338-1345 (2010).
91. Thomas, D.L. et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
92. Urban, T.J. et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 52, 1888-1896 (2010).
93. Terczyńska-Dyla, E. et al. Reduced IFN-λ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nat. Commun. 5, 5699 (2014).
94. Smith, K.R. et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 3, 57 (2011).
95. Ahlenstiel, G., Booth, D.R. & George, J. Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? Antivir. Ther. 17, 1163-1170 (2012).
96. Holmes, J.A., Desmond, P.V. & Thompson, A.J. Does IL28B genotyping still have a role in the era of direct-acting antiviral therapy for chronic hepatitis C infection? J. Viral Hepat. 19, 677-684 (2012).
97. Meissner, E.G. et al. IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. J. Infect. Dis. 209, 1700-1704 (2014).
98. Muir, A.J. IL28B in the era of direct-acting antivirals for hepatitis C. J. Clin. Gastroenterol. 47, 222-227 (2013).
99. Zeuzem, S. et al. Faldaprevir and deleobuvir for HCV genotype 1 infection. N. Engl. J. Med. 369, 630-639 (2013).
100. Bibert, S. et al. The IFNL3/4 ΔG variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients. AIDS 28, 1885-1889 (2014).
101. Manuel, O. et al. Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. J. Infect. Dis. 211, 906-914 (2015).
102. Hamming, O.J. et al. Interferon-λ4 signals via the IFN-λ receptor to regulate antiviral activity against HCV and coronaviruses. EMBO J. 32, 3055-3065 (2013).
103. Bochud, P.Y. et al. IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology 55, 384-394 (2012).
104. Eslam, M. et al. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Nat. Commun. 6, 6422 (2015).
105. Petta, S. et al. IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. J. Hepatol. 56, 1356-1362 (2012).
106. Noureddin, M. et al. Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: a longitudinal analysis. Hepatology 58, 1548-1557 (2013).
107. Jouvin-Marche, E. et al. Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. J. Infect. Dis. 209, 1907-1915 (2014).
108. Key, F.M. et al. Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon-λ4 (IFNL4). PLoS Genet. 10, e1004681 (2014).
109. Manry, J. et al. Evolutionary genetic dissection of human interferons. J. Exp. Med. 208, 2747-2759 (2011).
110. Kindler, E. et al. Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential. MBio 4, e00611-e00612 (2013).